Clinical Trials Browser

Interventional × Immunotherapy × Breast × Clear all

NCT03387553 2026-03-27

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT07254858 2025-11-28

CISN-L

Phase 2 Not yet recruiting

Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Phase NA Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06130826 2025-05-30

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Phase 1 Recruiting

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Phase 2 Not yet recruiting

HER2-Negative Locally Advanced Breast Cancer

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT02539017 2016-08-10

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Phase 2 Withdrawn

Triple Negative Breast Neoplasms